Race and ethnicity correlate with survival in patients with gastric adenocarcinoma
Open Access
- 21 July 2009
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 21 (1), 152-160
- https://doi.org/10.1093/annonc/mdp290
Abstract
Background: Asian centers have consistently reported superior gastric cancer outcomes. Our study examines gastric cancer survival among different races and ethnicities in a large, heterogeneous USA population. Patients and methods: Patients with gastric adenocarcinoma treated in Los Angeles County from 1988 to 2006 were identified from the Los Angeles County Cancer Surveillance Program. Patients were categorized by race and ethnicity as White, Asian, Hispanic and Black. Results: Of 13 084 patients, 39% were White, 22% Asian, 28% Hispanic, 11% Black and 2% other. Asian patients demonstrated higher survival than Whites, Hispanics and Blacks [median survival (MS) 16.3 versus 8.4, 8.7 and 7.9 months, respectively; log-rank P values < 0.001]. Multivariate Cox regression analysis showed that Asians had improved probability of survival [hazard ratio (HR) 0.76, 95% confidence interval (CI) 0.72–0.82; P < 0.001]. In patients who underwent curative-intent surgery, Asian patients demonstrated higher survival than Whites, Hispanics and Blacks (MS 32.7 versus 18.8, 19.9 and 18.9 months, respectively; log-rank P values < 0.001). Multivariate Cox regression analysis showed that Asians had improved probability of survival after surgery (HR 0.79, 95% CI 0.71–0.88; P < 0.001). Conclusions: Asians with gastric adenocarcinoma have superior outcomes in Los Angeles County. These outcomes verify disparities in gastric cancer survival among different races and ethnicities independent of established clinical and pathologic factors.This publication has 26 references indexed in Scilit:
- The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinomaCancer, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineNew England Journal of Medicine, 2007
- Learning Curve for Total Gastrectomy with D2 Lymph Node Dissection: Cumulative Sum Analysis for Qualified SurgeryAnnals of Surgical Oncology, 2006
- Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the WorldJournal of Clinical Oncology, 2006
- Gastric Cancer Surgery: Morbidity and Mortality Results From a Prospective Randomized Controlled Trial Comparing D2 and Extended Para-Aortic Lymphadenectomy—Japan Clinical Oncology Group Study 9501Journal of Clinical Oncology, 2004
- Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trialEuropean Journal of Surgical Oncology, 2004
- Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancerBritish Journal of Surgery, 2004
- Role of the Extended Lymphadenectomy in Gastric Cancer Surgery: Experience in a Single InstitutionAnnals of Surgical Oncology, 2003
- Gastric cancer: Different diseasesBritish Journal of Surgery, 1989